ArticleJournal of molecular histology2025
Investigation of the antidiabetic efficacy of Diabepat Kadha in type 2 diabetic Sprague-Dawley rats: modulation of GLUT4 expression as a molecular target.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and hyperglycemia. Adverse effects of synthetic antidiabetic drugs encourage interest in Ayurvedic alternatives. This study evaluated Diabepat Kadha, an Ayurvedic polyherbal formulation (HF), in streptozotocin (STZ) and nicotinamide (NA)-induced diabetic Sprague Dawley rats. T2DM was induced by 10% fructose solution for 14 days, followed by STZ (75 mg/kg) + NA (110 mg/kg) (STZ-NA) injection. Animals received 28-day treatments. Assessments included weekly glucose monitoring, oral glucose tolerance test (OGTT), serum insulin, creatinine, bleeding, clotting times, liver histopathology, skeletal muscle Glucose Transporter Type 4 (GLUT4 ) estimation, and gastric necropsy. STZ-NA significantly increased blood glucose (> 250 mg/dl) by day 4. HF (3 mL/kg), Metformin 200 mg/kg (M 200), and combination of HF(3 ml/kg) + Metformin 100 mg/kg (HF + M100) significantly reduced fasting glucose, restored insulin levels with favorable changes in HOMA indices, indicating enhanced insulin sensitivity and significant upregulation of. GLUT4 expression. OGTT exhibited improved glucose clearance, especially with HF + M100, restoring normalized levels within 120 min. Serum creatinine, bleeding, and clotting times remained unaltered. Diabetic controls showed marked hepato-cellular damage while treated groups exhibited near-normal hepatic architecture without gastric pathology. Diabepat Kadha demonstrated significant antidiabetic efficacy comparable to Metformin, with enhanced efficacy in combination. The formulation improved insulin sensitivity and glycemic control, primarily through upregulation of skeletal muscle GLUT4 expression by enhancement of insulin signaling and protection of hepatic architecture against STZ-induced injury as a result of synergy among various phytoconstituents in the formulation. Favorable safety profile further supports its therapeutic potential in T2DM management.
Indexed as
Identifiers
41288787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.